Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to cut the number of monthly migraine days (MMD) compared to placebo, with a ...

Quince (previously known as Cortexyme) is listed on the Nasdaq under the QNCX symbol, after completing a $75 million IPO in 2019. The company rebranded as Quince in 2022, and raised $22 million in a ...

PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Private equity firm expands healthcare focus. Inflexion, a leading European mid-market private equity firm, appointed John ...

ILiAD Biotechnologies leads this week's round-up of new private financings in the biopharma sector, with a $115 million Series B investment that will be used to test a new type of whooping cough ...

The pharmaceutical industry has long positioned itself as patient- or customer-focused. Our vision, mission and values statements are full of purpose-driven language, ethical intent, and references to ...

EVERSANA, a leading provider of commercialisation services to the global life sciences industry, has named Monica Avram as ...

In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...

According to Invest Europe, the challenge facing the European life sciences sector is clear - Europe currently accounts for ...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas. Built from ...

Zydus Lifesciences has reached a settlement agreement with Astellas in a patent dispute involving overactive bladder therapy Myrbetriq, which will allow its generic to remain on sale in the US.